Literature DB >> 15516027

Valproic acid induces expression of neutrophil chemoattractants of the CXC chemokine family in endothelial cells.

T Engl1, I Natsheh, I Müller, W D Beecken, D Jonas, R A Blaheta.   

Abstract

The branched-chain fatty acid valproate (valproic acid; VPA) displays antitumoral properties by blocking tumor growth, progression and invasion. Recent data have shown that VPA reduces the angiogenic activity of endothelial cells. The object of this study was to investigate whether endothelial modulation might also influence the level of chemotactic mediators. Endothelial cells were isolated from human umbilical cord veins (HUVEC) and treated with VPA-concentrations ranging from 0.125 mM to 1 mM. The mRNA level of CXC-chemokines was investigated by reverse transcriptase-polymerase chain reaction. The proliferative activity of HUVEC was measured as well. VPA evoked a striking increase in the neutrophil chemoattractants CXCL1, CXCL3, CXCL4, CXCL5 and a moderate increase in CXCL6 with maximal effects after a 3-day incubation period. Other CXC-chemokines and CXC-receptors remained unaffected. HUVEC growth was diminished time- and dose-dependently by VPA. We conclude that VPA treatment leads to alterations in the chemokine expression profile of endothelial cells. This might allow more neutrophils to reach the tumor area and trigger cytolysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516027     DOI: 10.5414/cpp42568

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  1 in total

1.  In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.

Authors:  Hilde Kvestad; Lasse Evensen; James B Lorens; Oystein Bruserud; Kimberley J Hatfield
Journal:  Leuk Res Treatment       Date:  2014-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.